Mar 30, 2023Alpha Tau Medical to Present at Jefferies Radiopharma Innovation SummitJERUSALEM, March 30, 2023 -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the...
Mar 12, 2023Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley BankJERUSALEM, March 12, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer...
Mar 10, 2023Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update- Opened U.S. pivotal trial in recurrent cutaneous squamous cell carcinoma, which began enrolling patients in March - - Received Health...
Mar 9, 2023Treatment of 1st two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) TrialAlpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial -First...
Mar 5, 2023Receipt of Increased Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval Alpha Tau Announces Receipt of Increased Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem...